Tagraxofusp, a CD123-targeted protein-drug conjugate and the first approved targeted treatment for BPDCN, might enhance outcomes especially in patients not eligible for intensive therapies. The gene discussed is IL3RA; the disease is CD4+/CD56+ hematodermic neoplasm.